New Target To Stop Cancer’s Spread Discovered By Georgia State University Scientists
News Feb 04, 2013
Cell migration is essential for the spread of cancerous cells, also known as metastasis, as well as for other diseases. The research team in the labs of Zhi-Ren Liu, professor of biology, and Jenny Yang, professor of biochemistry, studied the interaction of two molecules, p68 RNA helicase and calcium-calmodulin.
Interrupting the interaction between p68 and calcium-calmodulin, which is essential for cell migration, inhibited metastasis.
The findings were recently published in Nature Communications.
“Cancer, at its primary site, will not necessary kill,” Liu explained. “Cancer kills by multi-site metastasis. If we are able to disrupt this interaction, we will able to inhibit cancer metastasis. The research indicates that the interaction is absolutely required for all cell migration, and we suspect it may not be limited to cancerous-type cells. It may be a general phenomenon for all cell types.”
Calcium-calmodulin is an important protein, acting like a messenger to turn different proteins on and off, said Yang, whose lab focuses on calcium’s role in biological processes.
“Calmodulin is a very interesting protein and it interacts with many different systems in response to calcium level changes,” she said. “We have demonstrated a new target. There are new ways possible to modulate calcium signaling as a way to treat diseases.”
Because cell migration is a common phenomenon that is not only normal, but also related to diseases, there are impacts on treating other diseases, Liu said, from inflammation to neurodegenerative diseases and heart disease.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018